Genprex Inc (GNPX) Actualités

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa®...

Form 8-K - Current report

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire AUSTIN, Texas, Jan. 6...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for...

Form 8-K - Current report